{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:19:11Z","timestamp":1793744351953,"version":"4.6.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 108-2314-B-075-070-MY3"],"award-info":[{"award-number":["MOST 108-2314-B-075-070-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V110B-012"],"award-info":[{"award-number":["V110B-012"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chong Hin Loon Memorial Cancer and Biotherapy Research Center, National Yang Ming Chiao Tung University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Circulating monocytic myeloid-derived suppressive cells (M-MDSCs) are implicated as a poor prognostic factor and cause CAR T-cell failure in diffuse large B-cell lymphoma (DLBCL). Triggering receptors expressed on myeloid cells 2 (TREM2) are a transmembrane glycoprotein that polarize macrophages to anti-inflammation phenotype but have never been explored on M-MDSCs. This study aims to elucidate the expression and clinical impact of surface TREM2 on circulating M-MDSCs derived from DLBCL adults.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This prospective, observational study enrolled 100 adults with newly diagnosed and treatment-na\u00efve DLBCL from May 2019 to October 2021. Human circulating M-MDSCs were obtained from freshly isolated peripheral blood, and each patient\u2019s surface-TREM2 level on M-MDSCs was normalized via a healthy control at the same performance of flow-cytometry analysis. Murine MDSCs derived from bone marrow (BM-MDSCs) were adopted to assess the link between Trem2 and cytotoxic T lymphocytes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>More circulating M-MDSCs at diagnosis of DLBCL predicted worse progression-free (PFS) and overall survival (OS). Patients with higher IPI scores, bone marrow involvement, or lower absolute counts of CD4<jats:sup>+<\/jats:sup> or CD8<jats:sup>+<\/jats:sup> T cells in PB had significantly higher normalized TREM2 levels on M-MDSCs. Additionally, normalized TREM2 levels on M-MDSCs could be grouped into low (&lt;\u20092%), medium (2\u201344%), or high (&gt;\u200944%) levels, and a high normalized TREM2 level on M-MDSCs was proven as an independent prognostic factor for both PFS and OS via multivariate Cox regression analysis and associated with worst PFS and OS. Interestingly, normalized levels of surface TREM2 on M-MDSCs were negatively associated with absolute counts of PB CD8<jats:sup>+<\/jats:sup> T cells and positively correlated with levels of intracellular arginase 1 (ARG1) within M-MDSCs. Wild-type BM-MDSCs had significantly higher mRNA levels of <jats:italic>Arg1<\/jats:italic> and showed more prominent ability to suppress the proliferation of co-cultured CD8<jats:sup>+<\/jats:sup> T cells than BM-MDSCs from <jats:italic>Trem2<\/jats:italic> knockout mice, and the suppressive ability could be impaired by adding Arg1 inhibitors (CB1158) or supplementing L-arginine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In treatment-na\u00efve DLBCL adults, a high surface-TREM2 level on circulating M-MDSCs is a poor prognostic factor for both PFS and OS and warrants further investigation for its potential as a novel target in immunotherapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40164-023-00399-x","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T05:02:29Z","timestamp":1680843749000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Surface TREM2 on circulating M-MDSCs as a novel prognostic factor for adults with treatment-na\u00efve diffuse large B-cell lymphoma"],"prefix":"10.1186","volume":"12","author":[{"given":"Hao-Yuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Chen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Fen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Chung","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Shen","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Jung","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Kuang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Lin","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nien-Jung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,7]]},"reference":[{"issue":"26","key":"399_CR1","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1182\/bloodadvances.2017012534","volume":"1","author":"RW Merryman","year":"2017","unstructured":"Merryman RW, Armand P, Wright KT, Rodig SJ. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Adv. 2017;1(26):2643\u201354.","journal-title":"Blood Adv"},{"issue":"6","key":"399_CR2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1200\/JCO.18.00766","volume":"37","author":"SM Ansell","year":"2019","unstructured":"Ansell SM, Minnema MC, Johnson P, Timmerman JM, Armand P, Shipp MA, et al. Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study. J Clin Oncol. 2019;37(6):481\u20139.","journal-title":"J Clin Oncol"},{"issue":"26","key":"399_CR3","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New Engl J Med. 2017;377(26):2531\u201344.","journal-title":"New Engl J Med"},{"issue":"7","key":"399_CR4","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales M-A, Kersten M-J, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. New Engl J Med. 2022;386(7):640\u201354.","journal-title":"New Engl J Med"},{"issue":"1","key":"399_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. New Engl J Med. 2019;380(1):45\u201356.","journal-title":"New Engl J Med"},{"issue":"7","key":"399_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa2116596","volume":"386","author":"MR Bishop","year":"2022","unstructured":"Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. New Engl J Med. 2022;386(7):629\u201339.","journal-title":"New Engl J Med"},{"issue":"4","key":"399_CR7","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pag\u00e8s F, Saut\u00e8s-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298\u2013306.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"399_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nrc.2016.54","volume":"16","author":"C Engblom","year":"2016","unstructured":"Engblom C, Pfirschke C, Pittet MJ. The role of myeloid cells in cancer therapies. Nat Rev Cancer. 2016;16(7):447\u201362.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"399_CR9","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372\u201385.","journal-title":"Nat Rev Clin Oncol"},{"issue":"19","key":"399_CR10","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood.2020007445","volume":"137","author":"MD Jain","year":"2021","unstructured":"Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021;137(19):2621\u201333.","journal-title":"Blood"},{"issue":"1","key":"399_CR11","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-022-01335-y","volume":"15","author":"Y Wang","year":"2022","unstructured":"Wang Y, Johnson KCC, Gatti-Mays ME, Li Z. Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy. J Hematol Oncol. 2022;15(1):118.","journal-title":"J Hematol Oncol"},{"issue":"237","key":"399_CR12","doi-asserted-by":"publisher","first-page":"237ra67","DOI":"10.1126\/scitranslmed.3007974","volume":"6","author":"SL Highfill","year":"2014","unstructured":"Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, Morse E, et al. Disruption of CXCR2-mediated tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med. 2014;6(237):237ra67.","journal-title":"Sci Transl Med"},{"issue":"9","key":"399_CR13","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1172\/JCI80006","volume":"125","author":"S Ugel","year":"2015","unstructured":"Ugel S, De Sanctis F, Mandruzzato S, Bronte V. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest. 2015;125(9):3365\u201376.","journal-title":"J Clin Invest"},{"issue":"3","key":"399_CR14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162\u201374.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"399_CR15","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2010-05-283820","volume":"117","author":"Y Lin","year":"2011","unstructured":"Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB. Immunosuppressive CD14+HLA-DRlow\/\u2212 monocytes in B-cell non-Hodgkin lymphoma. Blood. 2011;117(3):872\u201381.","journal-title":"Blood"},{"issue":"9","key":"399_CR16","first-page":"15173","volume":"8","author":"C Wu","year":"2015","unstructured":"Wu C, Wu X, Zhang X, Chai Y, Guo Q, Li L, et al. Prognostic significance of peripheral monocytic myeloid-derived suppressor cells and monocytes in patients newly diagnosed with diffuse large b-cell lymphoma. Int J Clin Exp Med. 2015;8(9):15173\u201381.","journal-title":"Int J Clin Exp Med"},{"issue":"2","key":"399_CR17","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1159\/000445644","volume":"39","author":"C Wu","year":"2016","unstructured":"Wu C, Wu X, Liu X, Yang P, Xu J, Chai Y, et al. Prognostic significance of monocytes and monocytic myeloid-derived suppressor cells in diffuse large B-cell lymphoma treated with R-CHOP. Cell Physiol Biochem. 2016;39(2):521\u201330.","journal-title":"Cell Physiol Biochem"},{"issue":"12","key":"399_CR18","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/ni1411","volume":"7","author":"J Klesney-Tait","year":"2006","unstructured":"Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and signal integration. Nat Immunol. 2006;7(12):1266\u201373.","journal-title":"Nat Immunol"},{"issue":"5","key":"399_CR19","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1084\/jem.20141732","volume":"212","author":"K Wu","year":"2015","unstructured":"Wu K, Byers DE, Jin X, Agapov E, Alexander-Brett J, Patel AC, et al. TREM-2 promotes macrophage survival and lung disease after respiratory viral infection. J Exp Med. 2015;212(5):681\u201397.","journal-title":"J Exp Med"},{"issue":"4","key":"399_CR20","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1371\/journal.pmed.0040124","volume":"4","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, Prinz M, Stagi M, Chechneva O, Neumann H. TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. PLos Med. 2007;4(4):675\u201389.","journal-title":"PLos Med"},{"issue":"1","key":"399_CR21","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1073\/pnas.0803343106","volume":"106","author":"H Seno","year":"2009","unstructured":"Seno H, Miyoshi H, Brown SL, Geske MJ, Colonna M, Stappenbeck TS. Efficient colonic mucosal wound repair requires Trem2 signaling. P Nat Acad Sci. 2009;106(1):256\u201361.","journal-title":"P Nat Acad Sci"},{"issue":"2","key":"399_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1164\/rccm.201211-1967OC","volume":"188","author":"Q Chen","year":"2013","unstructured":"Chen Q, Zhang K, Jin Y, Zhu T, Cheng B, Shu Q, et al. Triggering receptor expressed on myeloid cells-2 protects against polymicrobial sepsis by enhancing bacterial clearance. Am J Resp Crit Care Med. 2013;188(2):201\u201312.","journal-title":"Am J Resp Crit Care Med"},{"issue":"14","key":"399_CR23","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"The international non-Hodgkin\u2019s lymphoma prognostic factors project","year":"1993","unstructured":"The international non-Hodgkin\u2019s lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin\u2019s\u2019s lymphoma. New Engl J Med. 1993;329(14):987\u201394.","journal-title":"New Engl J Med"},{"issue":"1","key":"399_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275\u201382.","journal-title":"Blood"},{"issue":"28","key":"399_CR25","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","volume":"30","author":"NA Johnson","year":"2012","unstructured":"Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452\u20139.","journal-title":"J Clin Oncol"},{"issue":"8","key":"399_CR26","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","volume":"117","author":"SM Aukema","year":"2011","unstructured":"Aukema SM, Siebert R, Schuuring E, Imhoff GW, Kluin-Nelemans HC, Boerma EJ, et al. Double-hit B-cell lymphomas. Blood. 2011;117(8):2319\u201331.","journal-title":"Blood"},{"issue":"2","key":"399_CR27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","volume":"19","author":"F Veglia","year":"2018","unstructured":"Veglia F, Perego M, Gabrilovich DI. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19(2):108\u201319.","journal-title":"Nat Immunol"},{"key":"399_CR28","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1038\/ncomms12150","volume":"7","author":"V Bronte","year":"2016","unstructured":"Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.","journal-title":"Nat Commun"},{"issue":"12","key":"399_CR29","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1016\/j.celrep.2016.11.062","volume":"17","author":"CR Lee","year":"2016","unstructured":"Lee CR, Kwak Y, Yang T, Han JH, Park SH, Ye MB, et al. Myeloid-derived suppressor cells are controlled by regulatory T cells via TGF-\u03b2 during murine colitis. Cell Rep. 2016;17(12):3219\u201332.","journal-title":"Cell Rep"},{"issue":"18","key":"399_CR30","doi-asserted-by":"publisher","first-page":"e2558","DOI":"10.21769\/BioProtoc.2558","volume":"7","author":"G Mondanelli","year":"2017","unstructured":"Mondanelli G, Volpi C. Differentiation of myeloid-derived suppressor cells from murine bone marrow and their co-culture with splenic dendritic cells. Bio Protoc. 2017;7(18):e2558.","journal-title":"Bio Protoc"},{"issue":"6","key":"399_CR31","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/S1471-4906(03)00132-7","volume":"24","author":"V Bronte","year":"2003","unstructured":"Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 2003;24(6):302\u20136.","journal-title":"Trends Immunol"},{"issue":"6","key":"399_CR32","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.4049\/jimmunol.177.6.3520","volume":"177","author":"IR Turnbull","year":"2006","unstructured":"Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, et al. Cutting edge: TREM-2 attenuates macrophage activation. J Immunol. 2006;177(6):3520\u20134.","journal-title":"J Immunol"},{"key":"399_CR33","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3389\/fimmu.2014.00532","volume":"5","author":"M Rath","year":"2014","unstructured":"Rath M, M\u00fcller I, Kropf P, Closs EI, Munder M. Metabolism via arginase or nitric oxide synthase: two competing arginine pathways in macrophages. Front Immunol. 2014;5:532.","journal-title":"Front Immunol"},{"issue":"4","key":"399_CR34","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.cell.2020.06.032","volume":"182","author":"Y Katzenelenbogen","year":"2020","unstructured":"Katzenelenbogen Y, Sheban F, Yalin A, Yofe I, Svetlichnyy D, Jaitin DA, et al. Coupled scRNA-Seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer. Cell. 2020;182(4):872\u201385.","journal-title":"Cell"},{"issue":"4","key":"399_CR35","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1158\/0008-5472.CAN-08-1921","volume":"69","author":"PC Rodriguez","year":"2009","unstructured":"Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, et al. Arginase I\u2013producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009;69(4):1553\u201360.","journal-title":"Cancer Res"},{"issue":"8","key":"399_CR36","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrc3774","volume":"14","author":"DW Scott","year":"2014","unstructured":"Scott DW, Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer. 2014;14(8):517\u201334.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"399_CR37","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s12185-014-1576-0","volume":"99","author":"S Kumagai","year":"2014","unstructured":"Kumagai S, Tashima M, Fujikawa J, Iwasaki M, Iwamoto Y, Sueki Y, et al. Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphoma. Int J Hematol. 2014;99(6):737\u201342.","journal-title":"Int J Hematol"},{"issue":"4","key":"399_CR38","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s00277-013-1916-9","volume":"93","author":"YL Li","year":"2014","unstructured":"Li YL, Pan YY, Jiao Y, Ning J, Fan YG, Zhai ZM. Peripheral blood lymphocyte\/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens. Ann Hematol. 2014;93(4):617\u201326.","journal-title":"Ann Hematol"},{"issue":"12","key":"399_CR39","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.7150\/jca.50552","volume":"12","author":"F Gao","year":"2021","unstructured":"Gao F, Hu J, Zhang J, Xu Y. Prognostic value of peripheral blood lymphocyte\/monocyte ratio in lymphoma. J Cancer. 2021;12(12):3407\u201317.","journal-title":"J Cancer"},{"key":"399_CR40","doi-asserted-by":"publisher","first-page":"6384","DOI":"10.3390\/cancers13246384","volume":"13","author":"J Carreras","year":"2021","unstructured":"Carreras J, Hiraiwa S, Kikuti YY, Miyaoka M, Tomita S, Ikoma H, et al. Artificial neural networks predicted the overall survival and molecular subtypes of diffuse large B-cell lymphoma using a pancancer immune-oncology panel. Cancers. 2021;13:6384.","journal-title":"Cancers"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-023-00399-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-023-00399-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-023-00399-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T10:12:04Z","timestamp":1681899124000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-023-00399-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,7]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["399"],"URL":"https:\/\/doi.org\/10.1186\/s40164-023-00399-x","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,7]]},"assertion":[{"value":"23 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hospital (no. 2019-04-015CC, 2020-07-024BCF and 2022-01-031CC), and written informed consent was obtained from each enrolled patient with respect to the use of their blood for scientific purposes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"This study was approved by the Institutional Review Board of Taipei Veterans General Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}